Watchlist Price Alert

Keros Therapeutics Inc. (KROS)

NASDAQ: KROS · Real-Time Price · USD

13.79

-0.77 (-5.26%)

At close: May 06, 2025, 3:59 PM

14.37

4.21%

Pre-market: May 07, 2025, 05:47 AM EDT

-5.26% (1D)

Bid	11.71
Market Cap	560.03M
Revenue (ttm)	3.55M
Net Income (ttm)	-187.35M
EPS (ttm)	-5
PE Ratio (ttm)	-2.76
Forward PE	-3.42
Analyst	Hold

Ask	14.4
Volume	812,778
Avg. Volume (20D)	1,087,175
Open	14.35
Previous Close	14.55
Day's Range	13.53 - 14.40
52-Week Range	9.12 - 72.37
Beta	1.32

About KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in pat...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 8, 2020

Employees 169

Stock Exchange NASDAQ

Ticker Symbol KROS

Website https://www.kerostx.com

Full Company Profile

Analyst Forecast

According to 13 analyst ratings, the average rating for KROS stock is "Hold." The 12-month stock price forecast is $25, which is an increase of 81.29% from the latest price.

Stock Forecasts

Earnings Surprise

New

Keros Therapeutics has released their quartely earnings on May 6, 2025:

Revenue of $211.25M exceeds estimates by $154.6M, with 254413.25% YoY growth.

EPS of 3.62 exceeds estimates by 3.61, with 399.17% YoY growth.

Why Price Moved

3 weeks ago

+18.49%

Keros Therapeutics shares are trading higher. The ... Unlock content with Pro Subscription

3 months ago

-16.51%

Keros Therapeutics shares are trading lower after the company announced an update on its Phase 2 TROPOS trial and halted all dosing based on the ongoing safety review.

News

1 day ago · zacks.com

Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates

Keros Therapeutics, Inc. (KROS) came out with quarterly earnings of $3.62 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $1.21 per share a year ...

3 weeks ago · zacks.com

KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%

The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.

3 weeks ago · benzinga.com

Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan

Keros Therapeutics, Inc.‘s KROS board of directors initiated a formal review process on Thursday to evaluate strategic alternatives, including a sale.

3 weeks ago · benzinga.com

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump

U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 4% on Thursday.

3 weeks ago · reuters.com

Keros Therapeutics adopts 'poison pill' plan

Keros Therapeutics said on Thursday its board had authorized a stockholder rights plan, also known as a "poison pill", in response to rapid accumulations of the company's stock by some investors.

1 month ago · zacks.com

Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 157% in Keros Therapeutics (KROS). While the effectiveness of this highly sought-after metric is questionable, ...

2 months ago · zacks.com

Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade

The mean of analysts' price targets for Keros Therapeutics (KROS) points to a 153.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am...

2 months ago · zacks.com

Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates

Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.34 per share a year ago.

2 months ago · accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS

NEW YORK, NY / ACCESS Newswire / February 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors a...